Sigma-Tau Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Clinical Trial Of STP206 For Prevention Of Necrotizing Enterocolitis In Very Low Birth Weight Premature Infants
Published: Feb 04, 2014
GAITHERSBURG, Md., Feb. 4, 2014 (GLOBE NEWSWIRE) -- Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) today announced that the first patient has been dosed as part of the Company's Phase I/II multi-center, double-blind, randomized, placebo-controlled clinical trial for STP206, in development for the prevention of necrotizing enterocolitis (NEC) in very low birth weight premature infants. STP206 is a live biotherapeutic being developed in the United States, under an FDA investigational new drug application (IND).
Help employers find you! Check out all the jobs and post your resume.